Human Insulin - Global Market Trajectory & Analytics

Global Human Insulin Market to Reach $102 Billion by 2027

Amid the COVID-19 crisis, the global market for Human Insulin estimated at US$49.9 Billion in the year 2020, is projected to reach a revised size of US$102 Billion by 2027, growing at a CAGR of 10.7% over the period 2020-2027. Analog, one of the segments analyzed in the report, is projected to record 11.2% CAGR and reach US$84.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Traditional segment is readjusted to a revised 8.9% CAGR for the next 7-year period.





The U.S. Market is Estimated at $13.5 Billion, While China is Forecast to Grow at 14.2% CAGR

The Human Insulin market in the U.S. is estimated at US$13.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$22 Billion by the year 2027 trailing a CAGR of 14.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 9.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Select Competitors (Total 43 Featured):

• Becton, Dickinson and Company
• Biocon Limited
• Biodel, Inc.
• Boehringer Ingelheim International GmbH
• Boston Scientific Corp.
• Braun Melsungen AG
• ELI Lilly and Company
• Julphar (Also Known as Gulf Pharmaceutical Industries)
• Medtronic Plc
• Merck & Co., Inc.
• NOVO Nordisk A/S
• Sanofi
• Tonghua Dongbao Pharmaceutical
• Wockhardt Limited
• Ypsomed AG